



Causal effects of serum sex hormone binding protein levels on the risk of amyotrophic lateral sclerosis: a mendelian randomization study

Ya-Nan Ou¹, Liu Yang², Bang-Sheng Wu², Lan Tan¹, Jin-Tai Yu²

¹Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China; ²Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China

Contributions: (I) Conception and design: JT Yu; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: YN Ou, L Yang, BS Wu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Prof. Jin-Tai Yu, MD, PhD. Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, 12th WulumuqiZhong Road, Shanghai 200040, China. Email: jintai_yu@fudan.edu.cn. Prof. Lan Tan, MD, PhD. Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao 266071, China. Email: dr.tanlan@163.com.

Background: Extensive observational studies have suggested an association between serum sex-hormone binding globulin (SHBG) and Alzheimer's disease (AD); however, causality remains unclear. Furthermore, the effects on other neurodegenerative diseases have been poorly investigated. We aimed to explore the causal effects of genetically predicted SHBG serum levels on common neurodegenerative diseases.

Methods: A two-sample Mendelian randomization (MR) approach was used. Genetic variants of SHBG levels in the serum, detected using the chemiluminescent two-step sandwich immunoassay method, were identified from a genome-wide association meta-analysis from the UK Biobank (N=363,228). Summary-level data for AD, and other common neurodegenerative diseases including Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD) were adopted from the corresponding large genome-wide association studies of individuals of European ancestry, which were either clinically or autopsy-diagnosed. Causal estimates were calculated using the inverse-variance weighted (IVW) method and several sensitivity methods (MR-Egger, weighted median, and weighted mode). Egger intercept, MR-PRESSO, and leave-one-out analyses were used to identify potential violations.

Results: Genetically determined serum SHBG levels [odds ratio (OR_{IVW}) =1.113, 95% CI: 1.019–1.215, P=0.017] were associated with an increased risk of ALS. This causal effect was confirmed using sensitivity analyses, including the MR-Egger (OR =1.229, 95% CI: 1.049–1.441, P=0.012), weighted median (OR =1.231, 95% CI: 1.077–1.406, P=0.002), and weighted mode (OR =1.235, 95% CI: 1.067–1.431, P=0.005) methods. No notable heterogeneity or directional pleiotropy was observed. However, leave-one-out analysis showed that rs9892297 drove the observed effects. There was no evidence that genetically predicted serum SHBG levels affect other neurodegenerative diseases, including AD, PD, MS, DLB, and FTD (all P>0.05).

Conclusions: This MR analysis found that genetically determined serum SHBG was associated with an increased risk of ALS rather than AD, which is inconsistent with previous observational studies. This novel finding highlights the potential of SHBG in peripheral serum for ALS prevention. Further research into the effects of SHBG on other neurodegenerative diseases is required, especially because of the increased utilization of hormone therapy.

Keywords: Sex hormone binding protein; amyotrophic lateral sclerosis (ALS); Alzheimer's disease (AD); neurodegenerative diseases; Mendelian randomization (MR)

Submitted Mar 04, 2022. Accepted for publication Aug 12, 2022.

doi: 10.21037/atm-22-1156

View this article at: <https://dx.doi.org/10.21037/atm-22-1156>

Introduction

Because of extended lifespans, the prevalence of age-related neurodegenerative disorders is increasing (1). These disorders impair individuals' memory, cognition, mood, and movement, but currently none are curable; existing treatments can only manage the symptoms or delay disease progression. Thus, viable biomarkers of aging-related neurodegenerative diseases, especially in peripheral blood, are crucial for the early warning, diagnosis, and treatment of these diseases (2).

Sex hormones have been reported to play an important role in human brain development, showing neuroprotective effects by preserving neural function and promoting neuronal survival (3). Sex-hormone binding globulin (SHBG) is a hepatically secreted binding protein for sex hormones in plasma that prevents hormones from binding to intracellular androgen or estrogen receptors (4). Thus, it is considered the major factor controlling the balance between biologically active testosterone and estradiol (4). Emerging evidence indicates that peripheral SHBG levels might be an effective indicator of the occurrence or progression of neurodegenerative disorders (5). However, inconsistencies and uncertainties exist and causality remains unclear. Higher SHBG has been found to be associated with worse cognitive performance and an increased risk of developing Alzheimer's disease (AD) and all-cause dementia (6). Recently, by integrating information from two databases, the Chinese Alzheimer's Biomarker and Lifestyle (CABLE) study and Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, our research team found that plasma SHBG could be a predictive biomarker for AD progression (5). However, the effects of SHBG on other neurodegenerative diseases have been poorly investigated. A previous Polish study revealed no difference in SHBG levels between Parkinson's disease (PD) patients and healthy subjects (7). In addition, a subtle relationship between SHBG and amyotrophic lateral sclerosis (ALS) has been revealed, which might be explained by the possible involvement of testosterone in ALS causation (8). However, the exploration of other neurological disorders remains controversial.

In addition, existing studies are limited to observational designs, which are subject to confounding bias and

reverse causation (9). Although epidemiological studies have adjusted for confounding factors observed in study participants, confounding bias is inevitable (10). Reverse causality bias arises if preclinical states that lead to outcomes also affect their risk factors (10). People consciously reduce their exposure to risk factors after acquiring an illness. Mendelian randomization (MR) is a technique that allows the examination of causal relationships (10). This method minimizes confounding bias because genetic variants are randomly allocated during conception. Reverse causality bias is also precluded because the genotypes are not affected by the disease. MR assesses lifelong exposure to health-related outcomes; thus, it can reveal potential causal associations (11). It is becoming increasingly viable, as data from numerous large genome-wide association studies (GWAS) over the past decade are now publicly available. The MR approach has been employed to uncover the causal effects of many risk factors regarding the incidence of neurodegenerative diseases (12-15).

We conducted a two-sample MR study to explore the causal effects of genetically predicted SHBG levels in the serum on common neurodegenerative diseases such as AD, including maternal/paternal family history of AD, as well as PD, ALS, multiple sclerosis (MS), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). We present the following article in accordance with the STROBE-MR reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-1156/rc>).

Methods

Study design and instrument identification

Two-sample MR analysis is a genetic instrumental variable (IV) analysis based on summary-level data with single nucleotide polymorphisms (SNPs) as instruments for risk factors. This method has been widely used. The MR approach is based on three assumptions as follows: (I) the genetic variants are significantly associated with SHBG levels in serum; (II) the IVs (namely, SNPs) have no association with confounding factors; and (III) the risks of outcomes (the six neurodegenerative diseases) are influenced only by exposure (serum SHBG), not by other pathways (16) (*Figure 1*). This study analyzed publicly available summary




Figure 1 Scheme diagram of the Mendelian randomization design. The MR approach should satisfy three assumptions. 1: the genetic variants significantly associate with the exposures; in this study, the two exposures are serum SHBG levels and neurological disorders; 2: the IVs (namely, SNPs) have no association with confounding factors; 3: the risk of outcome (neurological disorders) is influenced only by the exposure (serum SHBG), not by other pathways. MR, Mendelian randomization; SHBG, sex-hormone binding globulin; SNP, single nucleotide polymorphism.

level data from large GWASs. Informed consents and ethical approvals were obtained for the original studies. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Significant SNPs ($P < 5 \times 10^{-8}$) for serum SHBG levels were identified in a GWAS meta-analysis that included 363,228 individuals of European ancestry drawn from the UK Biobank (UKB) (17). The UKB was established in 2006 and enrolled participants from the entire UK population, with a recruitment age of 45–69 years. This study evaluated the genetic basis of 35 blood and urine laboratory measurements and identified 1,857 loci associated with at least one trait. Serum SHBG level was one of the 35 variables. Serum SHBG levels (nmol/L) were detected using the chemiluminescent two-step sandwich immunoassay method in Beckman Coulter DXI 800 (Beckman Coulter, UK), Ltd. The good or acceptable distribution rate was 95%. Further detailed information is provided in [Table S1](#).

Outcome databases

The outcomes of AD, PD, ALS, MS, DLB, and FTD were all clinically diagnosed or autopsy-diagnosed. The genetic variants associated with AD were extracted from the following GWAS summary statistics: (I) the International Genomics of Alzheimer's Project (IGAP) GWAS Stage 1 result ($N=21,982$ cases, 41,944 controls) (18); (II) maternal family history of AD ($N=27,696$ cases, 260,980 controls); and (III) paternal family history of AD ($N=14,338$ cases, 245,941 controls) (19). Late-onset AD was either autopsy-confirmed or clinically confirmed. Maternal and paternal family histories of AD were self-reported ([Table S1](#)). The

data of maternal and paternal family history of AD were extracted from the same dataset (UKB) as SHBG; thus, there was considerable overlap between the exposure and outcome samples. We only considered this part of the analysis as supplementary to support our main findings.

A recently published PD GWAS meta-analysis, which included three sources of data (three previously published GWAS studies, 13 new datasets, and proxy-case data from the UKB), was used as the PD GWAS source ($N=37,688$ cases, 18,618 UKB proxy-cases, and 1.4 million controls) (20). Summary statistics for ALS were obtained from a large GWAS involving 80,610 participants of European descent (20,806 ALS cases and 59,804 controls) (21). Patients were diagnosed with probable or definite ALS according to the EI Escorial criteria (22). The MS GWAS data leveraged genotype data from 47,429 MS cases and 68,374 controls of European descent from the International Multiple Sclerosis Genetics Consortium (23). DLB data were obtained from whole-genome sequencing of a cohort of 2,981 patients diagnosed with DLB and 4,391 neurologically healthy individuals (24). Participants were recruited from 44 institutions/consortia and diagnosed according to the established consensus criteria. FTD data were obtained from a two-stage GWAS with samples from 3,526 clinical FTD patients and 9,402 healthy controls (25). To reduce genetic heterogeneity, all the participants were of European ancestry ([Table S1](#)).

Instrument selection

We estimated the overall effect of serum SHBG on multiple neurodegenerative diseases by combining the effects of genome-wide significant SNPs ($P < 5 \times 10^{-8}$) from the GWAS,




Figure 2 A flow diagram of the process in this MR analysis. SNP, single nucleotide polymorphism; GWAS, genome-wide association studies; IV, instrumental variable; LD, linkage disequilibrium; AD, Alzheimer's disease; PD, Parkinson's disease; ALS, amyotrophic lateral sclerosis; MS, multiple sclerosis; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; MR, Mendelian randomization; SHBG, sex hormone binding globulin.

which were then clumped based on the European 1000 Genomes panel to a stringent LD threshold ($R^2 < 0.00001$) and then a default LD threshold ($R^2 < 0.001$). Several SNPs were further excluded to eliminate the genetic bias produced by the palindrome with intermediate allele frequencies. Eventually, 131 SNPs were included in late-onset AD, 130 SNPs for maternal AD, 130 SNPs for paternal AD, 130 SNPs for PD, 131 SNPs for ALS, 125 SNPs for MS, 122 SNPs for DLB, and 109 SNPs for FTD. There were no SNPs with F-statistics < 10 . The screening process is shown in *Figure 2*, and the included SNPs are shown in [Tables S2-S9](#).

Statistical analyses

Causal effects were estimated using the random-effects maximum likelihood estimation method. We applied four complementary methods [inverse variance weighted (IVW), MR-Egger, weighted median, and weighted mode], which provided different assumptions regarding horizontal

pleiotropy (26). The IVW method was performed as our primary method, which combined the Wald ratio estimates of the causal effects obtained from different SNPs. The intercept was assumed to be zero and associated with a weighted regression of SNP-exposure effects with SNP-outcome effects (27). MR-Egger regression is not constrained to have a slope of zero; therefore, its causal estimate represents a genotype-outcome dose-response relationship that takes pleiotropic effects into account (26,28). The weighted median approach is defined as the median of a weighted empirical density function of the ratio estimates, giving more weight to more precise IVs. The estimate is consistent even when up to 50% of the information comes from invalid or weak instruments (10). Results were presented as odds ratios (ORs) and 95% CIs. The MR-Egger intercept, MR-PRESSO global test, and Cochran Q statistics were used to test for the presence of heterogeneity or directional pleiotropy (29). The leave-one-SNP-out analysis was performed by systematic removal of




Figure 3 Mendelian randomization results of serum SHBG level and neurodegenerative diseases. Genome-wide significantly associated ($P < 5 \times 10^{-8}$) independent (linkage disequilibrium $R^2 = 0.00001$, clumping distance = 10,000 kb) SNPs were used as instruments. Bold fonts represent significant results. SNP, single nucleotide polymorphism; OR, odds ratio; MR, Mendelian randomization; AD, Alzheimer's disease; PD, Parkinson's disease; ALS, amyotrophic lateral sclerosis; MS, multiple sclerosis; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; SHBG, sex-hormone binding globulin.

genetic instruments from MR analysis to identify influential outliers. F-statistics were used to measure the strength of the genetic instruments in IVW (30). The F-statistics were >10 , indicating that the instrument strength was sufficient for MR analysis and less likely to be influenced by weak instrument bias (31).

Statistical significance of the above analyses was set at a 2-sided P value of <0.05 . Statistical analyses were conducted using R (version 3.6.3), and MR analyses were conducted using “TwoSampleMR”.

Results

Genetically determined serum SHBG levels and AD risk

No obvious significant causal association between genetically determined serum SHBG levels and the risk of late-onset

AD was found ($OR_{IVW} = 0.948$, 95% CI: 0.854–1.052, $P = 0.315$; SNPs = 131; *Figure 3*, *Figure S1*), whereas the results of the sensitivity analysis using the weighted median method were suggestive of protective effects with an OR of 0.862 (95% CI: 0.740–1.004, $P = 0.057$). Additional analysis applying an $R^2 < 0.001$ showed similar results (*Figures S2, S3*). There was evidence of heterogeneity in the causal effect estimates (P for MR-Egger = $4.71E-05$, P for IVW = $5.37E-05$; *Table 1*). The MR-PRESSO global test revealed horizontal pleiotropic effects ($P < 0.001$). However, no significant outliers were observed. Similar null associations between maternal and paternal AD were identified using 130 IVs. No evidence for heterogeneity of effect sizes (Cochran Q statistic, $P > 0.05$) or pleiotropy (intercept: $2.39E-04$, $P = 0.959$; P for MR-PRESSO global test = 0.953) was found for paternal AD, while evidence of heterogeneity

Table 1 Heterogeneity, pleiotropy and F-statistics analysis

Neurodegenerative diseases	No. of SNPs	Heterogeneity analysis			Pleiotropy analysis			MR-PRESSO			Leave-one-out analysis		F-statistics	
		Method	Q	P	Egger intercept	SE	P	Global test (P)	Outlier test	Distortion test (P)	Outlier corrected P	No		No
Late-onset AD	131	MR Egger	201.419	4.71E-05	0.002	0.003	0.553	<0.001	No outliers	NA	NA	NA	No	162.09
		IWV	201.971	5.37E-05										
Maternal AD	130	MR Egger	160.291	0.028	0.002	0.004	0.588	0.044	No outliers	NA	NA	NA	No	153.85
		IWV	160.66	0.031										
Paternal AD	130	MR Egger	102.755	9.51E-01	2.39E-04	0.005	0.959	0.953	NA	NA	NA	NA	No	153.85
		IWV	102.758	9.57E-01										
PD	130	MR Egger	202.163	3.20E-05	0.005	0.004	0.309	0.202	NA	NA	NA	NA	No	153.85
		IWV	203.811	2.96E-05										
ALS	131	MR Egger	155.66	0.055	-0.004	0.003	0.144	0.051	NA	NA	NA	NA	rs9892297	166.54
		IWV	158.268	0.046										
MS	125	MR Egger	966.791	5.13E-131	0.006	0.009	0.478	<0.001	rs10069690, rs10838681, rs12569576, rs17826544, rs2618566, rs2642420, rs62580767, rs6736913, rs7694379, rs7994151	NA	NA	0.465	No	166.54
		IWV	970.77	2.53E-131										
DLB	122	MR Egger	127.707	0.298	-0.018	0.007	0.014	0.189	NA	NA	NA	NA	No	146.97
		IWV	134.263	0.193										
FTD	109	MR Egger	105.083	0.534	0.011	0.009	0.203	0.534	NA	NA	NA	NA	No	158.91
		IWV	106.726	0.517										

SNP, single nucleotide polymorphism; MR, Mendelian randomization; IWV, inverse-variance weighted; SE, standard error; AD, Alzheimer's disease; PD, Parkinson's disease; ALS, amyotrophic lateral sclerosis; MS, multiple sclerosis; DLB, Dementia with Lewy Bodies; FTD frontotemporal dementia; NA, not available.

existed in the causal effect estimates for maternal AD (P for MR Egger =0.028, P for IVW =0.031; P for MR-PRESSO global test =0.044). There was no distortion in the leave-one-out and single-SNP plots, suggesting that no single SNP was driving the observed effect in any of the analyses (Figures S4-S6). The F-statistics for the three association pairs were 162.19, 153.85, and 153.85.

Genetically determined serum SHBG and other neurodegenerative diseases

The IVW method failed to support a causal relationship between serum SHBG and PD, with an OR of 1.020 (95% CI: 0.891–1.169, P=0.772; SNPs =130; Figure 3, Figure S1). This effect was supported by the weighted mode method (OR =0.831, 95% CI: 0.683–1.010, P=0.065). Additional analyses (LD $R^2 < 0.001$) using MR-Egger (OR =0.795, 95% CI: 0.638–0.990, P=0.042; SNPs =193) and weighted mode (OR =0.827, 95% CI: 0.700–0.977, P=0.027; SNPs =193) methods showed a supportive association (Figures S2,S3). Evidence for the heterogeneity of effect sizes (P for MR Egger =3.20E-05, P for IVW =2.96E-05; Table 1) was revealed. Nonetheless, horizontal pleiotropic effects were absent (intercept: 0.005, P=0.309; P for the MR-PRESSO global test =0.202). We did not find a single genetic variant of SHBG that influenced the association in the leave-one-out analysis (Figure S7). The F-statistic value was 153.85.

Interestingly, the results showed a statistically significant causal effect of genetically predicted serum SHBG levels on ALS (OR_{IVW} =1.113, 95% CI: 1.019–1.215, P=0.017; Figure 3, Figure S1). The causal effect was confirmed by sensitivity analyses including MR-Egger (OR_{MR-Egger} =1.229, 95% CI: 1.049–1.441, P=0.012), weighted median (OR_{weighted median} =1.231, 95% CI: 1.077–1.406, P=0.002), and weighted mode (OR_{weighted mode} =1.235, 95% CI: 1.067–1.431, P=0.005) methods (Figures S2,S3). Almost no evidence of heterogeneity of effect sizes (P for MR Egger =0.055, P for IVW =0.046; Table 1) or directional pleiotropy (intercept: -0.004, P=0.144; P for MR-PRESSO global test =0.051) was found. However, rs9892297 significantly drove the overall direction (Figure S8). The F statistics of 166.54 indicated that the association was less likely to be affected by weak instrumental bias.

No causal effects of SHBG on MS (125 SNPs), DLB (122 SNPs), or FTD (109 SNPs) were observed (Figure 3, Figure S1). Additional analyses supported these findings (Figures S2,S3). Cochran's Q statistics (P for MR Egger

=5.13E-131, P for IVW =2.53E-131) indicated notable heterogeneity across instrument SNP effects for MS (Table 1). The MR-PRESSO global test indicated pleiotropy (P<0.001). Although several outliers were identified, the overall null causal effect remained unchanged. Directional pleiotropy by Egger analysis was found for DLB (intercept: -0.018, P=0.014). No heterogeneity or pleiotropy was detected in the FTD analysis (all P>0.05). No single SNP was found to drive the above associations (Figures S9-S11). The F-statistics for the three association pairs were 166.54, 146.97, and 158.91, respectively.

Discussion

To the best of our knowledge, this is the first two-sample MR study to examine the causal associations between serum SHBG levels and several common neurodegenerative diseases. We revealed that genetically predicted serum SHBG levels were associated with the risk of developing ALS but did not provide solid MR evidence to support the causal effects on AD (including maternal and paternal family history of AD), PD, MS, DLB, or FTD. These results should be interpreted with caution, given that some of our results may be driven by genetic pleiotropy and heterogeneity. However, the consistency of our results across MR methods strengthens our inference of causality. Overall, these results will help interpret the results from current observational studies and indicate the direction of future application of hormone replacement therapy (HRT).

Our MR study revealed the deleterious effects of SHBG on ALS. Few observational studies have explored the association between SHBG and ALS. ALS is a progressive neurodegenerative disorder characterized by the involvement of both upper and lower motor neurons (32). It has been postulated that testosterone may play a role in ALS (8). In patients susceptible to ALS, there is possibly a sort of "testosterone resistance" at the level of the blood-brain barrier (BBB) commencing from birth (8). In these patients, testosterone at low levels can penetrate the BBB and enter the central neural axis. Then, 5 α -reductase in the anterior pituitary converts testosterone into dihydrotestosterone (DHT). DHT deficiency can lead to motor neuron death, ultimately leading to ALS. SHBG is a major factor controlling the balance between biologically active sex hormones (4). Higher SHBG levels are associated with lower levels of biologically active free testosterone. Obviously, with advancing age, the circadian excursion in free non-SHBG-binding testosterone declines, resulting

in a decrease in free testosterone available for intracerebral transport. Thus, susceptibility to ALS increases in individuals with BBB “testosterone resistance” (4). This is probably the reason for the increased incidence of ALS with age. To our knowledge, this is the first MR study to use genetic instruments, showing that genetically determined serum SHBG levels are causally associated with ALS. Our study sheds light on the causal relationship between SHBG and ALS, and highlights the potential of SHBG as a biomarker for ALS.

Accumulating observational studies have revealed significant associations between SHBG and AD risk (6) and pathologies (5,33). Nevertheless, the present MR analysis failed to support causality. We acknowledge several reasons for this finding. First, previous observational studies may have been affected by reverse causality and confounding bias (9). Increased SHBG levels are a surrogate marker for other known risk factors for dementia, especially age (34). Furthermore, many previous studies have demonstrated that high SHBG levels are associated with smoking, alcohol intake, lower physical activity, hyperinsulinemia, and metabolic syndrome (35,36), all of which have been reported to be related to AD development. Thus, it may be useful to consider SHBG as an early indicator of AD rather than as a direct modifier of AD risk. Second, the relationship between SHBG and AD may be complex and nonlinear, and could not be fully explored in our study. Thus, SHBG may exert stronger effects on later disease development. The association between SHBG and these diseases also largely depends on heterogeneous features (e.g., age, sex, and HRT). Therefore, further detailed studies are warranted. Third, the strength of current genetic variants may have contributed to discrepancies between phenotypic and MR associations, and the results may require updating as new genetic discoveries become available. Although previous observational studies have highlighted the association between serum SHBG and incident AD, it was not supported in the MR analysis.

Apart from AD, other null results should be interpreted with caution. The prevalence of PD is 1.5 times higher in men than in women (37). This evident sex difference in the occurrence of the disease suggests that sex hormones may alter an individual's susceptibility to the disease (38). However, a previous Polish study revealed no difference in SHBG levels between patients with PD (N=36) and healthy controls (N=69) (7). Therefore, further research is required to explore the effects of sex hormones and SHBG on PD.

To the best of our knowledge, few studies have investigated the effects of SHBG on MS, DLB, and FTD, and these associations warrant further investigation.

There are significant sex differences in the onset and progression of neurodegenerative diseases (39,40). Estrogens have been reported to exert neuroprotective effects through their action on cognate nuclear and membrane receptors (39). In the brain, sex hormones might affect a variety of signaling pathways, including catecholaminergic and acetylcholine pathways, which regulate cognition, motor, emotion, and other functions (41). Correspondingly, sex hormone receptors can induce various signaling cascades that mediate sex differences in neurodegenerative disorders (42). Furthermore, the preventive effects of HRT on cognitive impairment and dementia have been extensively studied (43). Unfortunately, these trials were not successful. Previous randomized controlled trials (RCTs) tended to focus on hormones (44,45) and rarely considered hormone transporters such as SHBG. Our MR research systematically interpreted the relationship between SHBG and neurodegenerative diseases, extending traditional observational associations to gene-mediated causality. It may be crucial for SHBG to be more widely included as a measure, along with other blood biomarkers, in hormone therapy studies or clinical trials.

Our study had several limitations that merit consideration. First, to avoid horizontal pleiotropy, a general challenge for MR, we used MR-PRESSO and MR-Egger regressions to estimate the extent to which heterogeneity and pleiotropy may bias the reported results. However, the possibility of heterogeneity and pleiotropy cannot be ruled out. Second, we cannot exclude the possibility of inflating the type 1 error rate because there were overlaps between exposure GWAS and outcome GWASs, especially for maternal and paternal family histories of AD. Third, it is important to recognize that MR measures the cumulative effect of lifelong exposure to genetic variants related to serum SHBG levels, unlike studies of the effects of discrete clinical interventions in adult life. Therefore, these MR results should not be extrapolated to determine the effect of SHBG on outcomes at a particular time period. Finally, the serum SHBG data were extracted from the UK biobank, a more educated, less deprived cohort, whose age range was 40–70 years, and thus might have poor representativeness of the UK general population. Moreover, since the majority of participants were of European ancestry, the results of this study are not necessarily applicable to other ethnicities.

Conclusions

Our findings highlight the important role of serum SHBG levels in neurodegenerative diseases, particularly ALS. Since the evaluation of sex hormones and SHBG in peripheral blood can be readily performed, they have the potential to be useful screening biomarkers for aging-related diseases. Further research is required regarding to study the role of SHBG, especially because of the increasing utilization of hormone therapy.

Acknowledgments

We would like to thank Editage (<https://www.editage.cn/>) for English language editing. This work was made possible by the generous sharing of GWAS summary statistics. We gratefully acknowledge the authors and participants of all GWAS from which we used summary statistics data. We thank Kunkle *et al.*, Marioni *et al.*, Nalls *et al.*, Nicolas *et al.*, International Multiple Sclerosis Genetics Consortium, Chia *et al.*, and Ferrari *et al.* for the late-onset AD, familial AD, PD, ALS, MS, DLB, and FTD GWAS summary results data. We also thank Sinnott-Armstrong *et al.* for the SHBG GWAS dataset. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i-Select chips were funded by the French National Foundation on AD and related disorders. EADI was supported by the LABEX DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2, and the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant No. 503480), Alzheimer's Research UK (Grant No. 503176), the Wellcome Trust (Grant No. 082604/2/07/Z), and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant No. 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA grant R01 AG033193 and the NIAAG081220 and AGES contract N01-AG-12100, the NHLBI grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01AG016976, and the Alzheimer's Association grant ADGC-10-196728. The investigators within above consortiums contributed to the design and implementation of the GWAS datasets and/or provided data but did not participate in analysis or writing of this report.

Funding: This study was supported by grants from the National Natural Science Foundation of China

(Nos. 82071201, 91849126, 82071997), Shanghai Municipal Science and Technology Major Project (No. 2018SHZDZX01), Research Start-up Fund of Huashan Hospital (No. 2022QD002), Excellence 2025 Talent Cultivation Program at Fudan University (No. 3030277001), and ZHANGJIANG LAB, Tianqiao and Chrissy Chen Institute, and the State Key Laboratory of Neurobiology and Frontiers Center for Brain Science of Ministry of Education, Fudan University.

Footnote

Reporting Checklist: The authors have completed the STROBE-MR reporting checklist. Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-1156/rc>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-1156/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The current analyses based on publicly available summary data and therefore does not require ethical approval. Original studies have been approved by ethic committees and written informed consent was obtained from study participants or caregivers. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Heemels MT. Neurodegenerative diseases. *Nature* 2016;539:179.
2. Turner MR. The early biomarker challenge in neurodegenerative disorders. *J Neurol Neurosurg*

- Psychiatry 2019;90:1190-1.
3. Veiga S, Melcangi RC, Doncarlos LL, et al. Sex hormones and brain aging. *Exp Gerontol* 2004;39:1623-31.
 4. Rosner W. The functions of corticosteroid-binding globulin and sex hormone-binding globulin: recent advances. *Endocr Rev* 1990;11:80-91.
 5. Xu W, Su BJ, Shen XN, et al. Plasma sex hormone-binding globulin predicts neurodegeneration and clinical progression in prodromal Alzheimer's disease. *Aging (Albany NY)* 2020;12:14528-41.
 6. Muller M, Schupf N, Manly JJ, et al. Sex hormone binding globulin and incident Alzheimer's disease in elderly men and women. *Neurobiol Aging* 2010;31(10):1758-1765.
 7. Nitkowska M, Tomasiuk R, Czyżyk M, et al. Prolactin and sex hormones levels in males with Parkinson's disease. *Acta Neurol Scand* 2015;131:411-6.
 8. Sawal N, Kaur J, Kaur K, Gombar S. Dihydrotestosterone in Amyotrophic lateral sclerosis-The missing link? *Brain Behav* 2020;10:e01645.
 9. Xu J, Xia LL, Song N, et al. Testosterone, Estradiol, and Sex Hormone-Binding Globulin in Alzheimer's Disease: A Meta-Analysis. *Curr Alzheimer Res* 2016;13:215-22.
 10. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* 2018;362:k601.
 11. Walker VM, Davey Smith G, Davies NM, et al. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. *Int J Epidemiol* 2017;46:2078-89.
 12. Rasooly D, Patel CJ. Conducting a Reproducible Mendelian Randomization Analysis Using the R Analytic Statistical Environment. *Curr Protoc Hum Genet* 2019;101:e82.
 13. Domenighetti C, Sugier PE, Ashok Kumar Sreelatha A, et al. Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. *Mov Disord* 2022;37:857-64.
 14. Di H, Zhu Y, Xia W, et al. Bidirectional Mendelian randomization to explore the causal relationships between Sleep traits, Parkinson's disease and Amyotrophic lateral sclerosis. *Sleep Med* 2022;96:42-9.
 15. Yang Y, Musco H, Simpson-Yap S, et al. Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases. *Nat Commun* 2021;12:5641.
 16. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* 2014;23:R89-98.
 17. Sinnott-Armstrong N, Tanigawa Y, Amar D, et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. *Nat Genet* 2021;53:185-94.
 18. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat Genet* 2019;51:414-30. Erratum in: *Nat Genet* 2019;51:1423-4.
 19. Marioni RE, Harris SE, Zhang Q, et al. GWAS on family history of Alzheimer's disease. *Transl Psychiatry* 2018;8:99.
 20. Nalls MA, Blauwendraat C, Vallergera CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol* 2019;18:1091-102.
 21. Nicolas A, Kenna KP, Renton AE, et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. *Neuron* 2018;97:1268-1283.e6.
 22. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. *J Neurol Sci* 1994;124 Suppl:96-107.
 23. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science* 2019;365:eaav7188.
 24. Chia R, Sabir MS, Bandres-Ciga S, et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. *Nat Genet* 2021;53:294-303.
 25. Ferrari R, Hernandez DG, Nalls MA, et al. Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurol* 2014;13:686-99.
 26. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;44:512-25.
 27. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* 2013;37:658-65.
 28. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Hum Mol Genet* 2018;27:R195-208.
 29. Bowden J, Spiller W, Del Greco M F, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via

- the Radial plot and Radial regression. *Int J Epidemiol* 2018;47:1264-78.
30. Pichler I, Del Greco M F, Gögele M, et al. Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. *PLoS Med* 2013;10:e1001462.
 31. Burgess S, Thompson SG; CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol* 2011;40:755-64.
 32. Chiò A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review. *Amyotroph Lateral Scler* 2009;10:310-23.
 33. Gillett MJ, Martins RN, Clarnette RM, et al. Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. *J Alzheimers Dis* 2003;5:267-9.
 34. Diver MJ, Imtiaz KE, Ahmad AM, et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. *Clin Endocrinol (Oxf)* 2003;58:710-7.
 35. Muller M, den Tonkelaar I, Thijssen JH, et al. Endogenous sex hormones in men aged 40-80 years. *Eur J Endocrinol* 2003;149:583-9.
 36. Muller M, Grobbee DE, den Tonkelaar I, et al. Endogenous sex hormones and metabolic syndrome in aging men. *J Clin Endocrinol Metab* 2005;90:2618-23.
 37. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. *Arch Neurol* 1992;49:492-7.
 38. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2007;78:819-24.
 39. Vegeto E, Villa A, Della Torre S, et al. The Role of Sex and Sex Hormones in Neurodegenerative Diseases. *Endocr Rev* 2020;41:bnz005.
 40. Nebel RA, Aggarwal NT, Barnes LL, et al. Understanding the impact of sex and gender in Alzheimer's disease: A call to action. *Alzheimers Dement* 2018;14:1171-83.
 41. Velez LM, Van C, Moore T, et al. Genetic variation of putative myokine signaling is dominated by biological sex and sex hormones. *Elife* 2022;11:76887.
 42. Sumien N, Cunningham JT, Davis DL, et al. Neurodegenerative Disease: Roles for Sex, Hormones, and Oxidative Stress. *Endocrinology* 2021;162:bqab185.
 43. Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, et al. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. *BMJ* 2019;364:l665.
 44. Zhou HH, Yu Z, Luo L, et al. The effect of hormone replacement therapy on cognitive function in healthy postmenopausal women: a meta-analysis of 23 randomized controlled trials. *Psychogeriatrics* 2021;21:926-38.
 45. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. *JAMA* 2013;310:1353-68.

Cite this article as: Ou YN, Yang L, Wu BS, Tan L, Yu JT. Causal effects of serum sex hormone binding protein levels on the risk of amyotrophic lateral sclerosis: a mendelian randomization study. *Ann Transl Med* 2022;10(19):1054. doi: 10.21037/atm-22-1156

Table S1 Basic characteristics of included GWASs used in the present MR analysis

GWAS type	PMID	Sources	Sample size (case/control)	Phenotype ascertainment
SHBG	33462484	UK Biobank	363,228	Detected by Chemiluminescent immunoassay
Late-onset AD	30820047	-	21,982/41,994	-
		ADGC	14,428/14,562	Autopsy-confirmed or clinically-confirmed
		CHARGE	2,137/13,474	Autopsy-confirmed or clinically-confirmed
		EADI	2,240/6,631	Autopsy-confirmed or clinically-confirmed
		GERAD/PERADES	3,177/7,277	Autopsy-confirmed or clinically-confirmed
Paternal AD	29777097	UK Biobank	14,338/245,941	Self-reported
Maternal AD	29777097	UK Biobank	27,696/260,980	Self-reported
PD	31701892	Nalls and colleagues	13,708/95,282	Clinically-confirmed
		IPDGC-NeuroX	5,851/5,866	Clinically-confirmed
		PDWBS	6,476/302,042	Clinically-confirmed
		UK Biobank	18,618/436,419	Self-reported
		SGPD	1,169/968	Clinically-confirmed
		IPDGC	8,036/5,803	Clinically-confirmed
		Post-Chang, 23andMe	2,448/571,411	Clinically-confirmed
ALS	29566793	-	20,806/59,804	-
		Italy	2,853/2,143	Clinically-confirmed
		United Kingdom	449/226	Clinically-confirmed
		Belgium/France	1,150/595	Clinically-confirmed
		USA	3,777/33,365	Clinically-confirmed
		Van Rheenen Study	12,577/23,475	Clinically-confirmed
MS	31604244	International Multiple Sclerosis Genetics Consortium	47,429/68,374	Clinically-confirmed
DLB	33589841	44 institutions/consortia	2,981/4,391	Clinically-confirmed or pathologically-confirmed
FTD	24943344	44 international research groups	3,526/9,402	Clinically-confirmed or pathologically-confirmed

SHBG, serum sex hormone binding protein; GWAS, Genome wide association study; MR, Mendelian randomization; ADGC, Alzheimer Disease Genetics Consortium; CHARGE, Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium; EADI, Genetic and Environmental Risk in AD/Defining Genetic; GERAD/PERADES, Polygenic and Environmental Risk for Alzheimer's Disease Consortium; UKB, UK Biobank; IPDGC, International Parkinson's Disease Genomics Consortium; PDWBS, Parkinson's disease web-based study; SGPD, Systems genomics of Parkinson's disease consortium; IPDGC, International Parkinson's Disease Genomics Consortium; AD, Alzheimer's disease; PD, Parkinson's disease; ALS, amyotrophic lateral sclerosis; MS, multiple sclerosis; DLB, Dementia with Lewy Bodies; FTD, frontotemporal dementia.

Table S2 SNP identified in AD GWAS

SNP	effect_allele	other_allele	eaf.exposure	eaf.outcome	beta.exposure	se.exposure	pval.exposure	beta.outcome	se.outcome	pval.outcome
rs10069690	T	C	NA	NA	-0.017	0.0028	2.13E-09	-0.0322	0.0215	0.1336
rs1060817	G	A	NA	NA	-0.0176	0.0025	5.12E-12	-0.0065	0.0147	0.6587
rs1076540	T	C	NA	NA	0.0169	0.0029	8.14E-09	0.0031	0.0168	0.8532
rs10838681	A	G	NA	NA	0.0162	0.0028	8.80E-09	0.0045	0.0165	0.7842
rs10871777	G	A	NA	NA	-0.0227	0.0029	8.41E-15	-0.0347	0.0168	0.03837
rs1106766	T	C	NA	NA	0.0357	0.0029	5.41E-34	0.0018	0.0171	0.9168
rs11075253	A	C	NA	NA	0.023	0.0028	6.30E-17	-0.0112	0.0159	0.48
rs11078405	T	G	NA	NA	-0.0293	0.0026	1.40E-29	-0.0324	0.0146	0.02596
rs1126670	A	C	NA	NA	-0.028	0.0027	1.35E-24	0.029	0.0156	0.06277
rs1128249	T	G	NA	NA	0.0286	0.0026	8.43E-29	-0.02	0.0145	0.1672
rs11550348	A	G	NA	NA	0.0536	0.0038	5.40E-46	-5.00E-04	0.0224	0.9816
rs116189680	A	G	NA	NA	0.1439	0.0077	6.52E-78	0.0036	0.059	0.9519
rs11626364	C	T	NA	NA	0.0237	0.0035	9.61E-12	0.0124	0.0199	0.5315
rs11636917	C	T	NA	NA	-0.0247	0.0026	1.06E-20	0.0315	0.0149	0.03406
rs11647008	C	T	NA	NA	-0.0249	0.0025	6.86E-23	0.0034	0.0144	0.8111
rs11655704	C	T	NA	NA	0.0785	0.0027	1.30E-189	-0.0124	0.0156	0.4284
rs11739158	T	C	NA	NA	0.0148	0.0025	4.85E-09	0.003	0.0143	0.8352
rs11748288	G	A	NA	NA	0.0167	0.0025	5.85E-11	0.0407	0.0145	0.005182
rs1183910	A	G	NA	NA	-0.0261	0.0027	6.73E-22	-0.0073	0.0154	0.638
rs11856886	G	A	NA	NA	0.0194	0.0027	1.27E-12	-0.0504	0.0155	0.001162
rs11887329	G	A	NA	NA	-0.0213	0.003	7.13E-13	-0.0108	0.0168	0.5217
rs11918018	A	G	NA	NA	-0.0153	0.0025	1.03E-09	0.0025	0.0143	0.8634
rs11935444	C	T	NA	NA	-0.0165	0.0026	4.11E-10	-0.0304	0.0144	0.03545
rs12192649	A	G	NA	NA	0.022	0.003	9.97E-14	-0.0021	0.0172	0.9039
rs12325400	G	C	NA	NA	-0.016	0.0026	4.03E-10	-0.0402	0.0148	0.006624
rs12414178	T	C	NA	NA	-0.0269	0.0029	5.57E-20	0.002	0.0169	0.9066
rs12569576	G	A	NA	NA	-0.017	0.0025	1.25E-11	0.006	0.0145	0.6804
rs12575636	G	T	NA	NA	-0.027	0.0033	1.36E-16	0.0294	0.0182	0.1055
rs1260326	C	T	NA	NA	0.0772	0.0026	4.58E-198	-0.0147	0.0145	0.3099
rs12748152	T	C	NA	NA	-0.0668	0.0046	2.79E-47	0.0207	0.0265	0.4358
rs12941564	G	C	NA	NA	0.0239	0.0028	1.31E-17	0.0205	0.0159	0.1952
rs13094241	G	T	NA	NA	0.0172	0.0028	1.04E-09	0.0194	0.0164	0.2364
rs13354321	C	T	NA	NA	0.0144	0.0025	1.44E-08	0.0144	0.015	0.3379
rs1421085	C	T	NA	NA	-0.0183	0.0026	8.91E-13	0.0026	0.0145	0.8601
rs1497406	G	A	NA	NA	0.027	0.0025	1.56E-26	0.0058	0.0145	0.69
rs1547014	C	T	NA	NA	-0.0293	0.0027	5.70E-28	-0.0283	0.0155	0.06867
rs1556562	T	G	NA	NA	0.0243	0.003	8.54E-16	-0.0262	0.0176	0.1379
rs157934	C	T	NA	NA	0.0229	0.0027	4.25E-17	-0.0216	0.0158	0.1702
rs1635852	C	T	NA	NA	0.0187	0.0025	6.54E-14	0.0376	0.0142	0.00836
rs16845803	G	A	NA	NA	-0.0251	0.0037	1.08E-11	0.0497	0.021	0.01808
rs17041868	C	T	NA	NA	-0.0346	0.005	6.49E-12	0.0232	0.0301	0.4405
rs1716403	C	T	NA	NA	-0.0168	0.0027	3.75E-10	0.0205	0.0153	0.1806
rs17202341	G	A	NA	NA	0.0157	0.0026	2.86E-09	-0.0157	0.015	0.296
rs17377148	G	T	NA	NA	0.0401	0.0048	1.13E-16	-0.029	0.0291	0.319
rs174601	T	C	NA	NA	-0.0252	0.0026	1.80E-22	-0.0032	0.0154	0.8335
rs1755618	T	G	NA	NA	-0.0252	0.0035	1.17E-12	0.0231	0.0215	0.2819
rs17580	A	T	NA	NA	0.0535	0.0059	1.54E-19	0.0636	0.0331	0.05506
rs17628931	C	T	NA	NA	0.0294	0.0041	4.71E-13	-0.0267	0.0228	0.2433
rs1772183	A	G	NA	NA	-0.022	0.0025	1.30E-18	-0.0026	0.0142	0.8518
rs17794619	A	G	NA	NA	-0.0347	0.0037	3.61E-21	0.0029	0.021	0.889
rs17826544	G	A	NA	NA	0.029	0.0026	3.87E-29	-0.0337	0.0148	0.02224
rs1801282	G	C	NA	NA	0.0377	0.0039	1.41E-22	-0.0267	0.022	0.2236
rs1801689	C	A	NA	NA	-0.0912	0.0074	6.69E-35	-0.0572	0.0465	0.2192
rs1832007	G	A	NA	NA	-0.0483	0.0035	3.66E-43	-0.0194	0.02	0.3328
rs1935	G	C	NA	NA	0.1198	0.0025	1.00E-200	-0.012	0.0142	0.3991
rs1982151	G	A	NA	NA	-0.049	0.0028	9.23E-67	0.0233	0.0161	0.1478
rs2081687	C	T	NA	NA	0.0247	0.0026	1.03E-20	0.0013	0.015	0.9326
rs2205262	A	C	NA	NA	-0.0167	0.0025	4.00E-11	-0.0309	0.0144	0.0323
rs2254069	A	G	NA	NA	-0.0265	0.0038	2.11E-12	0.0234	0.022	0.286
rs2266782	A	G	NA	NA	-0.0163	0.0025	1.25E-10	-0.0025	0.0145	0.8605
rs2335077	G	A	NA	NA	0.0463	0.0026	1.71E-69	-0.0043	0.0151	0.7761
rs2427530	A	G	NA	NA	0.0194	0.0029	2.99E-11	0.0263	0.0169	0.1196
rs2487826	C	T	NA	NA	0.0176	0.0025	3.56E-12	-0.0077	0.0143	0.592
rs2537855	G	A	NA	NA	0.0447	0.0028	3.56E-59	-0.0063	0.016	0.695
rs2618566	T	G	NA	NA	-0.0171	0.0026	8.57E-11	-0.0163	0.0154	0.292
rs2642420	A	C	NA	NA	-0.0247	0.0033	9.54E-14	-0.0295	0.0188	0.1176
rs2836950	G	C	NA	NA	-0.0154	0.0026	3.64E-09	-0.0052	0.0149	0.7274
rs2860075	G	A	NA	NA	-0.0289	0.0026	1.40E-28	-0.0187	0.0149	0.2105
rs28925904	T	C	NA	NA	-0.0576	0.0081	1.49E-12	0.0718	0.0595	0.2275
rs28929474	T	C	NA	NA	0.219	0.0091	5.87E-129	-0.0678	0.0562	0.2274
rs2943641	C	T	NA	NA	-0.0322	0.0026	6.16E-35	0.0123	0.0147	0.4024

Table S2 (continued)

Table S2 (continued)

SNP	effect_allele	other_allele	eaf.exposure	eaf.outcome	beta.exposure	se.exposure	pval.exposure	beta.outcome	se.outcome	pval.outcome
rs3132469	G	A	NA	NA	-0.033	0.0035	8.29E-21	-0.0492	0.0219	0.02476
rs34145453	G	A	NA	NA	0.0189	0.0026	2.90E-13	0.0188	0.0151	0.2138
rs34372369	A	G	NA	NA	0.037	0.0057	6.20E-11	-0.0137	0.0341	0.6869
rs35371479	T	C	NA	NA	0.0256	0.0033	7.00E-15	-0.0075	0.0182	0.6777
rs35386490	C	T	NA	NA	0.1118	0.003	1.00E-200	0.0271	0.022	0.2188
rs35627524	G	T	NA	NA	-0.0433	0.0067	1.09E-10	0.0337	0.0396	0.3949
rs3749237	A	G	NA	NA	-0.0257	0.0027	8.87E-22	-0.0094	0.0154	0.5388
rs3779195	A	T	NA	NA	-0.0768	0.0032	2.35E-126	-0.0019	0.0185	0.9191
rs3818247	T	G	NA	NA	-0.0247	0.0026	2.95E-21	-0.0084	0.0165	0.61
rs3848375	T	C	NA	NA	0.0231	0.0032	3.11E-13	-0.0253	0.0182	0.164
rs41302867	A	G	NA	NA	-0.0342	0.0039	8.26E-19	-0.0101	0.0225	0.6524
rs4149056	C	T	NA	NA	-0.067	0.0035	9.39E-81	0.0074	0.0198	0.7085
rs4381968	T	C	NA	NA	-0.0138	0.0025	4.23E-08	0.0092	0.0148	0.5345
rs440837	G	A	NA	NA	0.0466	0.0031	1.16E-50	0.0251	0.0171	0.1414
rs45512696	T	C	NA	NA	0.0407	0.0033	2.72E-34	-0.0012	0.0196	0.9494
rs45535039	C	T	NA	NA	0.0204	0.0028	3.34E-13	0.0064	0.016	0.6915
rs4639796	A	G	NA	NA	-0.0296	0.0034	3.23E-18	0.0078	0.0194	0.689
rs464605	T	C	NA	NA	-0.0323	0.0029	1.25E-29	0.0027	0.0167	0.8727
rs4660293	G	A	NA	NA	-0.0295	0.003	5.90E-23	0.0149	0.0167	0.3717
rs4690098	T	C	NA	NA	-0.0498	0.003	1.01E-61	-0.011	0.0175	0.5308
rs4822455	T	C	NA	NA	-0.0184	0.0025	3.48E-13	0.0055	0.0145	0.705
rs4983559	A	G	NA	NA	-0.0179	0.0026	2.85E-12	0.0213	0.0148	0.1489
rs555754	A	G	NA	NA	0.0343	0.0025	5.02E-42	0.0318	0.0143	0.02598
rs55707100	T	C	NA	NA	-0.1171	0.0081	1.76E-47	0.0253	0.0392	0.5184
rs55840085	A	G	NA	NA	0.0195	0.0026	6.35E-14	-0.0326	0.0153	0.03391
rs56196860	A	C	NA	NA	0.0478	0.0073	5.01E-11	0.0015	0.055	0.9788
rs5745687	T	C	NA	NA	0.0307	0.0051	2.07E-09	0.0158	0.0281	0.5739
rs57506806	G	A	NA	NA	0.0351	0.003	2.25E-32	-0.0162	0.0175	0.3548
rs58941251	T	C	NA	NA	-0.0241	0.0041	2.74E-09	0.0226	0.0229	0.3232
rs6129800	A	G	NA	NA	0.0239	0.003	1.35E-15	-0.0277	0.0177	0.1166
rs61935507	T	C	NA	NA	-0.0295	0.0037	1.50E-15	-0.0435	0.0217	0.04533
rs62576339	C	T	NA	NA	0.03	0.0029	8.22E-25	0.0309	0.0173	0.07435
rs62580767	C	T	NA	NA	0.0234	0.0033	8.54E-13	-0.0116	0.0186	0.5305
rs62618693	T	C	NA	NA	0.041	0.0061	1.93E-11	0.0205	0.0389	0.5985
rs6356	T	C	NA	NA	0.0199	0.0026	2.43E-14	0.0055	0.0154	0.7215
rs645040	T	G	NA	NA	-0.0691	0.003	9.86E-120	-0.035	0.017	0.03902
rs6736913	G	A	NA	NA	-0.0712	0.0089	1.12E-15	0.0521	0.0607	0.3909
rs6756943	A	G	NA	NA	-0.0448	0.0027	5.62E-61	0.0137	0.0156	0.3829
rs6954673	T	C	NA	NA	-0.0185	0.0026	1.27E-12	0.0137	0.0149	0.36
rs7221345	A	G	NA	NA	-0.0325	0.0026	3.13E-37	-0.0436	0.0147	0.003118
rs7239151	A	G	NA	NA	0.0155	0.0027	6.50E-09	0.0085	0.0156	0.5884
rs724577	C	A	NA	NA	-0.0186	0.0028	6.04E-11	0.0197	0.0162	0.2234
rs7250351	A	G	NA	NA	0.0229	0.0041	2.17E-08	-0.0131	0.026	0.6141
rs7250425	T	C	NA	NA	0.0179	0.0025	7.64E-13	-0.0091	0.0143	0.5266
rs72683923	C	T	NA	NA	0.0774	0.0092	5.67E-17	-0.1035	0.0504	0.03993
rs72756074	G	A	NA	NA	0.023	0.0038	1.65E-09	-0.044	0.0223	0.04856
rs7314285	G	T	NA	NA	0.0764	0.0048	3.82E-56	0.0525	0.0287	0.06707
rs738409	G	C	NA	NA	0.0486	0.003	5.06E-58	-0.0115	0.0176	0.5138
rs7429135	G	T	NA	NA	0.0199	0.0034	5.92E-09	-0.0107	0.0193	0.5778
rs750472	C	A	NA	NA	-0.0216	0.0025	4.22E-18	-0.0029	0.0146	0.84
rs76610881	G	A	NA	NA	0.0418	0.0041	7.29E-25	-0.05	0.026	0.05442
rs7694379	A	G	NA	NA	-0.042	0.0025	4.75E-62	-0.0142	0.0144	0.3236
rs7697204	T	C	NA	NA	-0.0295	0.0028	4.24E-25	0.0306	0.0162	0.05929
rs78025076	T	C	NA	NA	0.0503	0.0089	1.62E-08	-5.00E-04	0.0599	0.9927
rs78444298	A	G	NA	NA	-0.0613	0.0093	5.44E-11	-0.0322	0.0671	0.6314
rs7922067	A	G	NA	NA	-0.0211	0.0025	1.18E-16	0.0043	0.0146	0.7668
rs7947951	G	A	NA	NA	-0.0283	0.0027	9.37E-26	0.0308	0.0153	0.04386
rs7994151	G	A	NA	NA	-0.0206	0.0035	2.89E-09	-0.0116	0.02	0.5602
rs8017377	A	G	NA	NA	-0.0342	0.0025	3.92E-42	0.0025	0.0146	0.8614
rs8023580	C	T	NA	NA	0.073	0.0028	1.52E-150	-0.0196	0.016	0.2196
rs9316500	G	T	NA	NA	-0.0172	0.0027	3.05E-10	-0.0203	0.0154	0.1878
rs9332817	C	G	NA	NA	0.05	0.0079	3.09E-10	0.0029	0.0515	0.9553
rs9388768	A	C	NA	NA	-0.0197	0.0027	1.39E-13	0.0032	0.0153	0.8341
rs9427104	T	C	NA	NA	0.027	0.0025	4.04E-27	0.0102	0.0142	0.4726
rs9556403	G	A	NA	NA	0.0205	0.0026	4.66E-15	0.0097	0.0148	0.5152
rs9644032	G	T	NA	NA	-0.0159	0.0026	1.03E-09	0.0165	0.0151	0.2729
rs976002	G	A	NA	NA	0.035	0.0029	1.60E-33	-0.04	0.0208	0.05491
rs9892297	G	A	NA	NA	-0.1366	0.0026	1.00E-200	0.0206	0.0156	0.1862
rs9987289	G	A	NA	NA	0.0437	0.0043	3.22E-24	-0.027	0.0256	0.2921

SNP, single nucleotide polymorphism; AD, Alzheimer's disease; GWAS, genome-wide association studies; NA, not available.

Table S3 SNPs identified in maternal AD GWAS

SNP	effect_allele	other_allele	eaf.exposure	eaf.outcome	beta.exposure	se.exposure	pval.exposure	beta.outcome	se.outcome	pval.outcome
rs10069690	T	C	NA	NA	-0.017	0.0028	2.13E-09	-0.04975	0.020069	0.013183
rs1060817	G	A	NA	NA	-0.0176	0.0025	5.12E-12	0.011114	0.017727	0.530698
rs1076540	T	C	NA	NA	0.0169	0.0029	8.14E-09	-0.03771	0.020537	0.066347
rs10838681	A	G	NA	NA	0.0162	0.0028	8.80E-09	-0.02157	0.019742	0.274476
rs10871777	G	A	NA	NA	-0.0227	0.0029	8.41E-15	0.00919	0.02051	0.654094
rs1106766	T	C	NA	NA	0.0357	0.0029	5.41E-34	0.00723	0.020317	0.721935
rs11075253	A	C	NA	NA	0.023	0.0028	6.30E-17	0.009964	0.019106	0.602009
rs11078405	T	G	NA	NA	-0.0293	0.0026	1.40E-29	-0.06038	0.018153	0.00088
rs1126670	A	C	NA	NA	-0.028	0.0027	1.35E-24	0.042508	0.019103	0.026072
rs1128249	T	G	NA	NA	0.0286	0.0026	8.43E-29	-0.00314	0.017889	0.860462
rs11550348	A	G	NA	NA	0.0536	0.0038	5.40E-46	0.012394	0.02658	0.641011
rs116189680	A	G	NA	NA	0.1439	0.0077	6.52E-78	0.059445	0.05313	0.263204
rs11626364	C	T	NA	NA	0.0237	0.0035	9.61E-12	-0.00935	0.024285	0.700375
rs11636917	C	T	NA	NA	-0.0247	0.0026	1.06E-20	-0.00127	0.018388	0.944799
rs11647008	C	T	NA	NA	-0.0249	0.0025	6.86E-23	0.002747	0.017494	0.875211
rs11655704	C	T	NA	NA	0.0785	0.0027	1.30E-189	-0.00822	0.018772	0.661595
rs11739158	T	C	NA	NA	0.0148	0.0025	4.85E-09	0.030774	0.017659	0.08138
rs11748288	G	A	NA	NA	0.0167	0.0025	5.85E-11	0.035954	0.017768	0.04302
rs1183910	A	G	NA	NA	-0.0261	0.0027	6.73E-22	-0.02844	0.018986	0.134127
rs11856886	G	A	NA	NA	0.0194	0.0027	1.27E-12	-0.02242	0.018997	0.237999
rs11887329	G	A	NA	NA	-0.0213	0.003	7.13E-13	0.04302	0.020576	0.036543
rs11918018	A	G	NA	NA	-0.0153	0.0025	1.03E-09	-0.00128	0.017497	0.941567
rs11935444	C	T	NA	NA	-0.0165	0.0026	4.11E-10	-0.02784	0.017681	0.115325
rs12192649	A	G	NA	NA	0.022	0.003	9.97E-14	0.007127	0.020465	0.727665
rs12325400	G	C	NA	NA	-0.016	0.0026	4.03E-10	-0.05864	0.017852	0.00102
rs12414178	T	C	NA	NA	-0.0269	0.0029	5.57E-20	0.020264	0.02059	0.325038
rs12569576	G	A	NA	NA	-0.017	0.0025	1.25E-11	0.017522	0.017551	0.318111
rs12575636	G	T	NA	NA	-0.027	0.0033	1.36E-16	0.010212	0.022352	0.647784
rs1260326	C	T	NA	NA	0.0772	0.0026	4.58E-198	-0.02535	0.017866	0.155885
rs12748152	T	C	NA	NA	-0.0668	0.0046	2.79E-47	-0.05651	0.032357	0.080711
rs13094241	G	T	NA	NA	0.0172	0.0028	1.04E-09	0.028171	0.019659	0.151856
rs13354321	C	T	NA	NA	0.0144	0.0025	1.44E-08	-0.01184	0.017704	0.503463
rs1421085	C	T	NA	NA	-0.0183	0.0026	8.91E-13	-0.00103	0.017845	0.954007
rs1497406	G	A	NA	NA	0.027	0.0025	1.56E-26	0.009239	0.017692	0.601512
rs1547014	C	T	NA	NA	-0.0293	0.0027	5.70E-28	-0.01447	0.018588	0.436271
rs1556562	T	G	NA	NA	0.0243	0.003	8.54E-16	0.023992	0.020888	0.250723
rs157934	C	T	NA	NA	0.0229	0.0027	4.25E-17	0.041666	0.018926	0.027695
rs1635852	C	T	NA	NA	0.0187	0.0025	6.54E-14	0.037209	0.017447	0.032952
rs16845803	G	A	NA	NA	-0.0251	0.0037	1.08E-11	0.037215	0.02577	0.148706
rs17041868	C	T	NA	NA	-0.0346	0.005	6.49E-12	0.006253	0.035595	0.860559
rs1716403	C	T	NA	NA	-0.0168	0.0027	3.75E-10	0.000292	0.018711	0.987564
rs17202341	G	A	NA	NA	0.0157	0.0026	2.86E-09	-0.04017	0.018355	0.028618
rs17377148	G	T	NA	NA	0.0401	0.0048	1.13E-16	0.013581	0.033107	0.681663
rs174601	T	C	NA	NA	-0.0252	0.0026	1.80E-22	-0.0187	0.018059	0.300449
rs1755618	T	G	NA	NA	-0.0252	0.0035	1.17E-12	0.009397	0.025121	0.708361
rs17580	A	T	NA	NA	0.0535	0.0059	1.54E-19	0.032912	0.040338	0.414556
rs17628931	C	T	NA	NA	0.0294	0.0041	4.71E-13	0.034494	0.027983	0.217693
rs1772183	A	G	NA	NA	-0.022	0.0025	1.30E-18	-0.02406	0.017482	0.168719
rs17794619	A	G	NA	NA	-0.0347	0.0037	3.61E-21	0.017153	0.025239	0.496728
rs17826544	G	A	NA	NA	0.029	0.0026	3.87E-29	-0.01124	0.017917	0.530472
rs1801282	G	C	NA	NA	0.0377	0.0039	1.41E-22	-0.0397	0.027007	0.141575
rs1801689	C	A	NA	NA	-0.0912	0.0074	6.69E-35	0.039163	0.051242	0.444705
rs1832007	G	A	NA	NA	-0.0483	0.0035	3.66E-43	-0.01493	0.02418	0.536866
rs1935	G	C	NA	NA	0.1198	0.0025	1.00E-200	-0.01143	0.017513	0.514074
rs1982151	G	A	NA	NA	-0.049	0.0028	9.23E-67	0.00278	0.020023	0.889559
rs2081687	C	T	NA	NA	0.0247	0.0026	1.03E-20	0.025985	0.018514	0.160452
rs2205262	A	C	NA	NA	-0.0167	0.0025	4.00E-11	-0.01439	0.017643	0.41474
rs2254069	A	G	NA	NA	-0.0265	0.0038	2.11E-12	-0.02883	0.02696	0.28482
rs2266782	A	G	NA	NA	-0.0163	0.0025	1.25E-10	0.005005	0.017706	0.777443
rs2335077	G	A	NA	NA	0.0463	0.0026	1.71E-69	-0.01536	0.018375	0.403286
rs2427530	A	G	NA	NA	0.0194	0.0029	2.99E-11	0.032276	0.020215	0.110356
rs2487826	C	T	NA	NA	0.0176	0.0025	3.56E-12	0.003413	0.017699	0.847065
rs2537855	G	A	NA	NA	0.0447	0.0028	3.56E-59	0.002748	0.019308	0.886805
rs2618566	T	G	NA	NA	-0.0171	0.0026	8.57E-11	-0.00288	0.018439	0.875742
rs2642420	A	C	NA	NA	-0.0247	0.0033	9.54E-14	0.02142	0.023035	0.352429
rs2836950	G	C	NA	NA	-0.0154	0.0026	3.64E-09	-0.01037	0.018258	0.56994
rs2860075	G	A	NA	NA	-0.0289	0.0026	1.40E-28	-0.02624	0.018203	0.149397
rs28925904	T	C	NA	NA	-0.0576	0.0081	1.49E-12	0.049009	0.055511	0.377306
rs28929474	T	C	NA	NA	0.219	0.0091	5.87E-129	-0.07902	0.06239	0.205299
rs2943641	C	T	NA	NA	-0.0322	0.0026	6.16E-35	0.02516	0.018311	0.169429
rs3132469	G	A	NA	NA	-0.033	0.0035	8.29E-21	-0.0687	0.024243	0.004601

Table S3 (continued)

Table S3 (continued)

SNP	effect_allele	other_allele	eaf.exposure	eaf.outcome	beta.exposure	se.exposure	pval.exposure	beta.outcome	se.outcome	pval.outcome
rs34145453	G	A	NA	NA	0.0189	0.0026	2.90E-13	-0.01572	0.018144	0.386369
rs34372369	A	G	NA	NA	0.037	0.0057	6.20E-11	-0.02866	0.039921	0.472773
rs35371479	T	C	NA	NA	0.0256	0.0033	7.00E-15	-0.00291	0.022764	0.898447
rs35627524	G	T	NA	NA	-0.0433	0.0067	1.09E-10	-0.00499	0.046822	0.915169
rs3749237	A	G	NA	NA	-0.0257	0.0027	8.87E-22	0.031401	0.018598	0.091345
rs3779195	A	T	NA	NA	-0.0768	0.0032	2.35E-126	-0.00276	0.022467	0.902223
rs3818247	T	G	NA	NA	-0.0247	0.0026	2.95E-21	-0.02154	0.018208	0.23677
rs3848375	T	C	NA	NA	0.0231	0.0032	3.11E-13	-0.03109	0.022016	0.157866
rs41302867	A	G	NA	NA	-0.0342	0.0039	8.26E-19	-0.01366	0.026657	0.608229
rs4149056	C	T	NA	NA	-0.067	0.0035	9.39E-81	0.003491	0.024447	0.88646
rs4381968	T	C	NA	NA	-0.0138	0.0025	4.23E-08	-0.02557	0.017605	0.146309
rs440837	G	A	NA	NA	0.0466	0.0031	1.16E-50	0.014053	0.021725	0.517711
rs45512696	T	C	NA	NA	0.0407	0.0033	2.72E-34	-0.00257	0.023011	0.911089
rs45535039	C	T	NA	NA	0.0204	0.0028	3.34E-13	-0.00715	0.019683	0.716432
rs4639796	A	G	NA	NA	-0.0296	0.0034	3.23E-18	-0.01633	0.023883	0.494162
rs464605	T	C	NA	NA	-0.0323	0.0029	1.25E-29	0.009331	0.020068	0.641944
rs4660293	G	A	NA	NA	-0.0295	0.003	5.90E-23	-0.00076	0.020617	0.970436
rs4690098	T	C	NA	NA	-0.0498	0.003	1.01E-61	0.011287	0.020936	0.589816
rs4822455	T	C	NA	NA	-0.0184	0.0025	3.48E-13	0.01906	0.017717	0.282014
rs4983559	A	G	NA	NA	-0.0179	0.0026	2.85E-12	0.011058	0.017972	0.53837
rs555754	A	G	NA	NA	0.0343	0.0025	5.02E-42	-0.02461	0.017535	0.160432
rs55707100	T	C	NA	NA	-0.1171	0.0081	1.76E-47	0.020801	0.056002	0.710315
rs55840085	A	G	NA	NA	0.0195	0.0026	6.35E-14	-0.02055	0.018251	0.260097
rs56196860	A	C	NA	NA	0.0478	0.0073	5.01E-11	-0.00018	0.050003	0.99711
rs5745687	T	C	NA	NA	0.0307	0.0051	2.07E-09	0.014957	0.035291	0.671705
rs57506806	G	A	NA	NA	0.0351	0.003	2.25E-32	-0.00537	0.020742	0.795552
rs58941251	T	C	NA	NA	-0.0241	0.0041	2.74E-09	0.013725	0.028079	0.624973
rs6129800	A	G	NA	NA	0.0239	0.003	1.35E-15	-0.0062	0.020984	0.767685
rs61935507	T	C	NA	NA	-0.0295	0.0037	1.50E-15	0.02591	0.025598	0.311451
rs62576339	C	T	NA	NA	0.03	0.0029	8.22E-25	-0.01467	0.020522	0.47478
rs62580767	C	T	NA	NA	0.0234	0.0033	8.54E-13	0.018203	0.022597	0.420494
rs62618693	T	C	NA	NA	0.041	0.0061	1.93E-11	-0.06838	0.042581	0.108315
rs6356	T	C	NA	NA	0.0199	0.0026	2.43E-14	-0.00908	0.018221	0.618297
rs645040	T	G	NA	NA	-0.0691	0.003	9.86E-120	-0.01156	0.020855	0.5793
rs6736913	G	A	NA	NA	-0.0712	0.0089	1.12E-15	-0.06239	0.059873	0.297373
rs6756943	A	G	NA	NA	-0.0448	0.0027	5.62E-61	-0.04132	0.018983	0.029502
rs6954673	T	C	NA	NA	-0.0185	0.0026	1.27E-12	-0.04428	0.018208	0.015024
rs7221345	A	G	NA	NA	-0.0325	0.0026	3.13E-37	-0.0089	0.017841	0.61772
rs7239151	A	G	NA	NA	0.0155	0.0027	6.50E-09	-0.0092	0.018766	0.624028
rs724577	C	A	NA	NA	-0.0186	0.0028	6.04E-11	0.022927	0.019904	0.249355
rs7250351	A	G	NA	NA	0.0229	0.0041	2.17E-08	-0.0278	0.028758	0.333641
rs7250425	T	C	NA	NA	0.0179	0.0025	7.64E-13	0.011914	0.017454	0.494877
rs72683923	C	T	NA	NA	0.0774	0.0092	5.67E-17	-0.0454	0.063072	0.471632
rs72756074	G	A	NA	NA	0.023	0.0038	1.65E-09	0.016589	0.026625	0.533237
rs7314285	G	T	NA	NA	0.0764	0.0048	3.82E-56	-0.01136	0.034788	0.744064
rs738409	G	C	NA	NA	0.0486	0.003	5.06E-58	-0.01398	0.021208	0.50988
rs7429135	G	T	NA	NA	0.0199	0.0034	5.92E-09	0.033432	0.024004	0.163703
rs750472	C	A	NA	NA	-0.0216	0.0025	4.22E-18	0.024473	0.01745	0.160785
rs76610881	G	A	NA	NA	0.0418	0.0041	7.29E-25	-0.02824	0.028044	0.313925
rs7694379	A	G	NA	NA	-0.042	0.0025	4.75E-62	0.036783	0.017637	0.037014
rs7697204	T	C	NA	NA	-0.0295	0.0028	4.24E-25	0.01365	0.020044	0.495877
rs78025076	T	C	NA	NA	0.0503	0.0089	1.62E-08	0.025575	0.060588	0.672943
rs78444298	A	G	NA	NA	-0.0613	0.0093	5.44E-11	0.028472	0.063222	0.65246
rs7922067	A	G	NA	NA	-0.0211	0.0025	1.18E-16	-0.00241	0.017788	0.892303
rs7947951	G	A	NA	NA	-0.0283	0.0027	9.37E-26	0.023058	0.018943	0.223507
rs7994151	G	A	NA	NA	-0.0206	0.0035	2.89E-09	0.020986	0.024318	0.388133
rs8017377	A	G	NA	NA	-0.0342	0.0025	3.92E-42	-0.0082	0.017474	0.639014
rs8023580	C	T	NA	NA	0.073	0.0028	1.52E-150	0.034249	0.019539	0.079625
rs9316500	G	T	NA	NA	-0.0172	0.0027	3.05E-10	0.01171	0.01918	0.541516
rs9332817	C	G	NA	NA	0.05	0.0079	3.09E-10	0.064675	0.053767	0.229026
rs9388768	A	C	NA	NA	-0.0197	0.0027	1.39E-13	-0.0004	0.018594	0.982711
rs9427104	T	C	NA	NA	0.027	0.0025	4.04E-27	0.014845	0.017468	0.395426
rs9556403	G	A	NA	NA	0.0205	0.0026	4.66E-15	-0.0097	0.018275	0.59571
rs9644032	G	T	NA	NA	-0.0159	0.0026	1.03E-09	0.015264	0.018172	0.400912
rs976002	G	A	NA	NA	0.035	0.0029	1.60E-33	0.005158	0.020218	0.798654
rs9892297	G	A	NA	NA	-0.1366	0.0026	1.00E-200	-0.00086	0.018475	0.96286
rs9987289	G	A	NA	NA	0.0437	0.0043	3.22E-24	0.000249	0.030219	0.993415

SNP, single nucleotide polymorphism; AD, Alzheimer's disease; GWAS, genome-wide association studies; NA, not available.

Table S4 (continued)

SNP	effect_allele	other_allele	eaf.exposure	eaf.outcome	beta.exposure	se.exposure	pval.exposure	beta.outcome	se.outcome	pval.outcome
rs34145453	G	A	NA	NA	0.0189	0.0026	2.90E-13	-0.00726	0.024863	0.770353
rs34372369	A	G	NA	NA	0.037	0.0057	6.20E-11	-0.14677	0.056158	0.00896
rs35371479	T	C	NA	NA	0.0256	0.0033	7.00E-15	-0.03178	0.031314	0.310106
rs35627524	G	T	NA	NA	-0.0433	0.0067	1.09E-10	0.009379	0.06397	0.883439
rs3749237	A	G	NA	NA	-0.0257	0.0027	8.87E-22	0.022343	0.025506	0.381048
rs3779195	A	T	NA	NA	-0.0768	0.0032	2.35E-126	0.010341	0.030714	0.736358
rs3818247	T	G	NA	NA	-0.0247	0.0026	2.95E-21	0.015571	0.024915	0.53199
rs3848375	T	C	NA	NA	0.0231	0.0032	3.11E-13	-0.02232	0.030155	0.459143
rs41302867	A	G	NA	NA	-0.0342	0.0039	8.26E-19	-0.02121	0.036611	0.562456
rs4149056	C	T	NA	NA	-0.067	0.0035	9.39E-81	-0.03428	0.033676	0.30874
rs4381968	T	C	NA	NA	-0.0138	0.0025	4.23E-08	0.011557	0.024151	0.632273
rs440837	G	A	NA	NA	0.0466	0.0031	1.16E-50	-0.01537	0.029872	0.606892
rs45512696	T	C	NA	NA	0.0407	0.0033	2.72E-34	0.020937	0.031422	0.505199
rs45535039	C	T	NA	NA	0.0204	0.0028	3.34E-13	-0.05577	0.027105	0.039642
rs4639796	A	G	NA	NA	-0.0296	0.0034	3.23E-18	-0.00825	0.032714	0.800969
rs464605	T	C	NA	NA	-0.0323	0.0029	1.25E-29	0.045261	0.027593	0.100939
rs4660293	G	A	NA	NA	-0.0295	0.003	5.90E-23	0.002038	0.028232	0.942459
rs4690098	T	C	NA	NA	-0.0498	0.003	1.01E-61	-0.02998	0.028826	0.298342
rs4822455	T	C	NA	NA	-0.0184	0.0025	3.48E-13	-0.03383	0.024229	0.162612
rs4983559	A	G	NA	NA	-0.0179	0.0026	2.85E-12	-0.02573	0.024624	0.296063
rs555754	A	G	NA	NA	0.0343	0.0025	5.02E-42	0.037596	0.024003	0.117276
rs55707100	T	C	NA	NA	-0.1171	0.0081	1.76E-47	-0.03056	0.07737	0.692872
rs55840085	A	G	NA	NA	0.0195	0.0026	6.35E-14	0.00406	0.024955	0.870755
rs56196860	A	C	NA	NA	0.0478	0.0073	5.01E-11	-0.01378	0.068707	0.841072
rs5745687	T	C	NA	NA	0.0307	0.0051	2.07E-09	0.022354	0.048347	0.643816
rs57506806	G	A	NA	NA	0.0351	0.003	2.25E-32	-0.03413	0.028525	0.23155
rs58941251	T	C	NA	NA	-0.0241	0.0041	2.74E-09	-0.04286	0.038827	0.269696
rs6129800	A	G	NA	NA	0.0239	0.003	1.35E-15	-0.03177	0.028835	0.270503
rs61935507	T	C	NA	NA	-0.0295	0.0037	1.50E-15	-0.0216	0.035301	0.540645
rs62576339	C	T	NA	NA	0.03	0.0029	8.22E-25	-0.00374	0.028104	0.894238
rs62580767	C	T	NA	NA	0.0234	0.0033	8.54E-13	0.002738	0.031014	0.929657
rs62618693	T	C	NA	NA	0.041	0.0061	1.93E-11	0.089546	0.056422	0.112498
rs6356	T	C	NA	NA	0.0199	0.0026	2.43E-14	-0.00107	0.024953	0.965692
rs645040	T	G	NA	NA	-0.0691	0.003	9.86E-120	0.032156	0.028717	0.26281
rs6736913	G	A	NA	NA	-0.0712	0.0089	1.12E-15	-0.08076	0.081646	0.322598
rs6756943	A	G	NA	NA	-0.0448	0.0027	5.62E-61	-0.00496	0.026105	0.849376
rs6954673	T	C	NA	NA	-0.0185	0.0026	1.27E-12	0.013553	0.024893	0.586123
rs7221345	A	G	NA	NA	-0.0325	0.0026	3.13E-37	0.005746	0.02446	0.81427
rs7239151	A	G	NA	NA	0.0155	0.0027	6.50E-09	0.01719	0.025767	0.504677
rs724577	C	A	NA	NA	-0.0186	0.0028	6.04E-11	0.023265	0.027271	0.393603
rs7250351	A	G	NA	NA	0.0229	0.0041	2.17E-08	0.018732	0.039663	0.636724
rs7250425	T	C	NA	NA	0.0179	0.0025	7.64E-13	-0.00779	0.023925	0.744589
rs72683923	C	T	NA	NA	0.0774	0.0092	5.67E-17	-0.15275	0.088591	0.084679
rs72756074	G	A	NA	NA	0.023	0.0038	1.65E-09	0.017928	0.036502	0.623319
rs7314285	G	T	NA	NA	0.0764	0.0048	3.82E-56	0.039957	0.047256	0.397809
rs738409	G	C	NA	NA	0.0486	0.003	5.06E-58	-0.02489	0.029092	0.392318
rs7429135	G	T	NA	NA	0.0199	0.0034	5.92E-09	-0.01008	0.032709	0.757907
rs750472	C	A	NA	NA	-0.0216	0.0025	4.22E-18	-0.00383	0.023932	0.872961
rs76610881	G	A	NA	NA	0.0418	0.0041	7.29E-25	-0.03675	0.038569	0.340643
rs7694379	A	G	NA	NA	-0.042	0.0025	4.75E-62	-0.03434	0.024209	0.156057
rs7697204	T	C	NA	NA	-0.0295	0.0028	4.24E-25	-0.01931	0.027393	0.480888
rs78025076	T	C	NA	NA	0.0503	0.0089	1.62E-08	0.056965	0.082557	0.49019
rs78444298	A	G	NA	NA	-0.0613	0.0093	5.44E-11	-0.02181	0.087354	0.802838
rs7922067	A	G	NA	NA	-0.0211	0.0025	1.18E-16	0.005266	0.024388	0.829037
rs7947951	G	A	NA	NA	-0.0283	0.0027	9.37E-26	0.03278	0.025974	0.206929
rs7994151	G	A	NA	NA	-0.0206	0.0035	2.89E-09	-0.00099	0.033438	0.976361
rs8017377	A	G	NA	NA	-0.0342	0.0025	3.92E-42	-0.0229	0.023948	0.339014
rs8023580	C	T	NA	NA	0.073	0.0028	1.52E-150	0.016433	0.026841	0.540377
rs9316500	G	T	NA	NA	-0.0172	0.0027	3.05E-10	-0.00653	0.026328	0.803995
rs9332817	C	G	NA	NA	0.05	0.0079	3.09E-10	0.017483	0.074191	0.8137
rs9388768	A	C	NA	NA	-0.0197	0.0027	1.39E-13	-0.01245	0.025453	0.624764
rs9427104	T	C	NA	NA	0.027	0.0025	4.04E-27	0.007817	0.023958	0.744205
rs9556403	G	A	NA	NA	0.0205	0.0026	4.66E-15	0.007567	0.025027	0.762388
rs9644032	G	T	NA	NA	-0.0159	0.0026	1.03E-09	-0.02142	0.024853	0.388697
rs976002	G	A	NA	NA	0.035	0.0029	1.60E-33	-0.01877	0.027792	0.499477
rs9892297	G	A	NA	NA	-0.1366	0.0026	1.00E-200	0.007712	0.025278	0.7603
rs9987289	G	A	NA	NA	0.0437	0.0043	3.22E-24	0.013842	0.041485	0.738632

SNP, single nucleotide polymorphism; AD, Alzheimer's disease; GWAS, genome-wide association studies; NA, not available.

Table S8 (continued)

SNP	effect_allele	other_allele	eaf.exposure	eaf.outcome	beta.exposure	se.exposure	pval.exposure	beta.outcome	se.outcome	pval.outcome
rs3818247	T	G	NA	0.330767	-0.0247	0.0026	2.95E-21	0.016857	0.038899	0.664841
rs3848375	T	C	NA	0.816489	0.0231	0.0032	3.11E-13	-0.07451	0.047778	0.118874
rs41302867	A	G	NA	0.119444	-0.0342	0.0039	8.26E-19	-0.04102	0.056635	0.46887
rs4149056	C	T	NA	0.150981	-0.067	0.0035	9.39E-81	-0.00313	0.051724	0.951816
rs440837	G	A	NA	0.23181	0.0466	0.0031	1.16E-50	-0.02128	0.044604	0.633355
rs45512696	T	C	NA	0.152098	0.0407	0.0033	2.72E-34	-0.00898	0.050176	0.858041
rs45535039	C	T	NA	0.288428	0.0204	0.0028	3.34E-13	-0.02028	0.041364	0.623955
rs4639796	A	G	NA	0.16141	-0.0296	0.0034	3.23E-18	-0.07048	0.050735	0.164795
rs464605	T	C	NA	0.742985	-0.0323	0.0029	1.25E-29	0.042076	0.042286	0.319726
rs4660293	G	A	NA	0.232928	-0.0295	0.003	5.90E-23	0.007383	0.043254	0.864418
rs4690098	T	C	NA	0.23181	-0.0498	0.003	1.01E-61	-0.06162	0.043888	0.16034
rs4822455	T	C	NA	0.567917	-0.0184	0.0025	3.48E-13	0.00838	0.037555	0.823419
rs4983559	A	G	NA	0.622796	-0.0179	0.0026	2.85E-12	-0.03127	0.037885	0.409268
rs555754	A	G	NA	0.510678	0.0343	0.0025	5.02E-42	-0.0631	0.036812	0.086504
rs55840085	A	G	NA	0.371244	0.0195	0.0026	6.35E-14	-0.07872	0.038362	0.040155
rs56196860	A	C	NA	0.031041	0.0478	0.0073	5.01E-11	-0.10207	0.108608	0.347333
rs5745687	T	C	NA	0.073256	0.0307	0.0051	2.07E-09	-0.06318	0.074045	0.393509
rs57506806	G	A	NA	0.229451	0.0351	0.003	2.25E-32	-0.02601	0.044066	0.555086
rs58941251	T	C	NA	0.111622	-0.0241	0.0041	2.74E-09	-0.00215	0.059326	0.97109
rs6129800	A	G	NA	0.212317	0.0239	0.003	1.35E-15	0.005395	0.044497	0.903447
rs61935507	T	C	NA	0.141793	-0.0295	0.0037	1.50E-15	0.027498	0.053283	0.605827
rs62576339	C	T	NA	0.248945	0.03	0.0029	8.22E-25	0.019881	0.043206	0.645381
rs62580767	C	T	NA	0.184132	0.0234	0.0033	8.54E-13	-0.01178	0.048637	0.808604
rs62618693	T	C	NA	0.043705	0.041	0.0061	1.93E-11	-0.06574	0.090072	0.465456
rs6356	T	C	NA	0.370872	0.0199	0.0026	2.43E-14	0.044189	0.0383	0.248568
rs6736913	G	A	NA	0.98597	-0.0712	0.0089	1.12E-15	-0.12571	0.14852	0.39732
rs6756943	A	G	NA	0.689223	-0.0448	0.0027	5.62E-61	0.011513	0.040004	0.773499
rs6954673	T	C	NA	0.334741	-0.0185	0.0026	1.27E-12	0.078978	0.038955	0.04262
rs7221345	A	G	NA	0.60144	-0.0325	0.0026	3.13E-37	-0.00475	0.037421	0.899105
rs7239151	A	G	NA	0.700521	0.0155	0.0027	6.50E-09	0.020496	0.040513	0.612929
rs724577	C	A	NA	0.732804	-0.0186	0.0028	6.04E-11	0.081037	0.042269	0.055219
rs7250351	A	G	NA	0.896325	0.0229	0.0041	2.17E-08	-0.00444	0.059524	0.940562
rs7250425	T	C	NA	0.507946	0.0179	0.0025	7.64E-13	-0.01528	0.036954	0.679166
rs72683923	C	T	NA	0.015644	0.0774	0.0092	5.67E-17	-0.23903	0.154838	0.12266
rs72756074	G	A	NA	0.123417	0.023	0.0038	1.65E-09	-0.07891	0.057793	0.172139
rs7314285	G	T	NA	0.068413	0.0764	0.0048	3.82E-56	0.045079	0.071795	0.530119
rs738409	G	C	NA	0.234542	0.0486	0.003	5.06E-58	-0.06511	0.044247	0.141156
rs7429135	G	T	NA	0.835113	0.0199	0.0034	5.92E-09	0.019747	0.050787	0.697406
rs750472	C	A	NA	0.496896	-0.0216	0.0025	4.22E-18	0.039573	0.037268	0.288307
rs76610881	G	A	NA	0.094736	0.0418	0.0041	7.29E-25	0.068527	0.061505	0.265218
rs7694379	A	G	NA	0.415942	-0.042	0.0025	4.75E-62	-0.00325	0.037501	0.930974
rs7697204	T	C	NA	0.732804	-0.0295	0.0028	4.24E-25	0.068592	0.04261	0.107453
rs78025076	T	C	NA	0.017631	0.0503	0.0089	1.62E-08	0.023843	0.137623	0.862441
rs78444298	A	G	NA	0.01341	-0.0613	0.0093	5.44E-11	0.102809	0.152087	0.499062
rs7922067	A	G	NA	0.581202	-0.0211	0.0025	1.18E-16	-0.00152	0.03703	0.967229
rs7947951	G	A	NA	0.68078	-0.0283	0.0027	9.37E-26	0.013196	0.04006	0.741853
rs7994151	G	A	NA	0.156692	-0.0206	0.0035	2.89E-09	-0.06841	0.051743	0.186134
rs8017377	A	G	NA	0.475788	-0.0342	0.0025	3.92E-42	-0.00987	0.03729	0.791324
rs8023580	C	T	NA	0.297492	0.073	0.0028	1.52E-150	0.030646	0.040962	0.454405
rs9316500	G	T	NA	0.307673	-0.0172	0.0027	3.05E-10	0.033938	0.039851	0.394362
rs9332817	C	G	NA	0.028061	0.05	0.0079	3.09E-10	-0.17612	0.117168	0.132797
rs9388768	A	C	NA	0.674447	-0.0197	0.0027	1.39E-13	0.057391	0.039856	0.149884
rs9427104	T	C	NA	0.479017	0.027	0.0025	4.04E-27	0.01412	0.036981	0.70254
rs9556403	G	A	NA	0.365036	0.0205	0.0026	4.66E-15	0.025483	0.03841	0.507082
rs9644032	G	T	NA	0.626397	-0.0159	0.0026	1.03E-09	0.012262	0.03872	0.751479
rs976002	G	A	NA	0.219518	0.035	0.0029	1.60E-33	-0.00871	0.044898	0.846095
rs9892297	G	A	NA	0.328532	-0.1366	0.0026	1.00E-200	-0.04856	0.038982	0.212829
rs9987289	G	A	NA	0.922151	0.0437	0.0043	3.22E-24	0.033742	0.068998	0.624819

SNP, single nucleotide polymorphism; DLB, Dementia with Lewy Bodies; GWAS, genome-wide association studies; NA, not available.

Table S9 (continued)

SNP	effect_allele	other_allele	eaf.exposure	eaf.outcome	beta.exposure	se.exposure	pval.exposure	beta.outcome	se.outcome	pval.outcome
rs4149056	C	T	NA	NA	-0.067	0.0035	9.39E-81	0.1116	0.0556	0.04481
rs4381968	T	C	NA	NA	-0.0138	0.0025	4.23E-08	-0.0997	0.0411	0.0154
rs440837	G	A	NA	NA	0.0466	0.0031	1.16E-50	-0.0365	0.0456	0.4227
rs45512696	T	C	NA	NA	0.0407	0.0033	2.72E-34	-0.0092	0.0545	0.8656
rs45535039	C	T	NA	NA	0.0204	0.0028	3.34E-13	-0.0802	0.0506	0.1131
rs4639796	A	G	NA	NA	-0.0296	0.0034	3.23E-18	-0.0541	0.0642	0.3997
rs464605	T	C	NA	NA	-0.0323	0.0029	1.25E-29	0.0247	0.0501	0.6224
rs4660293	G	A	NA	NA	-0.0295	0.003	5.90E-23	0.0246	0.0479	0.6075
rs4690098	T	C	NA	NA	-0.0498	0.003	1.01E-61	-0.0202	0.0461	0.6604
rs4822455	T	C	NA	NA	-0.0184	0.0025	3.48E-13	-0.0074	0.0405	0.8558
rs4983559	A	G	NA	NA	-0.0179	0.0026	2.85E-12	-0.0513	0.0426	0.2283
rs555754	A	G	NA	NA	0.0343	0.0025	5.02E-42	-0.015	0.0392	0.7023
rs55707100	T	C	NA	NA	-0.1171	0.0081	1.76E-47	0.0607	0.1584	0.7018
rs55840085	A	G	NA	NA	0.0195	0.0026	6.35E-14	-0.0394	0.0417	0.3445
rs5745687	T	C	NA	NA	0.0307	0.0051	2.07E-09	0.0891	0.095	0.3486
rs57506806	G	A	NA	NA	0.0351	0.003	2.25E-32	0.0233	0.0582	0.6888
rs58941251	T	C	NA	NA	-0.0241	0.0041	2.74E-09	-0.1045	0.0655	0.1108
rs6129800	A	G	NA	NA	0.0239	0.003	1.35E-15	0.0186	0.0484	0.7003
rs62576339	C	T	NA	NA	0.03	0.0029	8.22E-25	0.0865	0.0503	0.0856
rs62580767	C	T	NA	NA	0.0234	0.0033	8.54E-13	-0.0198	0.0514	0.6994
rs62618693	T	C	NA	NA	0.041	0.0061	1.93E-11	-0.1912	0.1571	0.2237
rs6736913	G	A	NA	NA	-0.0712	0.0089	1.12E-15	0.0864	0.1714	0.6144
rs6756943	A	G	NA	NA	-0.0448	0.0027	5.62E-61	0.0112	0.044	0.7989
rs6954673	T	C	NA	NA	-0.0185	0.0026	1.27E-12	-0.0334	0.0405	0.4088
rs7221345	A	G	NA	NA	-0.0325	0.0026	3.13E-37	0.0271	0.0437	0.5353
rs7239151	A	G	NA	NA	0.0155	0.0027	6.50E-09	0.058	0.0451	0.1983
rs724577	C	A	NA	NA	-0.0186	0.0028	6.04E-11	0.0024	0.0442	0.9567
rs7250425	T	C	NA	NA	0.0179	0.0025	7.64E-13	0.0673	0.0391	0.08508
rs72683923	C	T	NA	NA	0.0774	0.0092	5.67E-17	0.0931	0.2179	0.669
rs7314285	G	T	NA	NA	0.0764	0.0048	3.82E-56	-0.0021	0.0755	0.9778
rs738409	G	C	NA	NA	0.0486	0.003	5.06E-58	-0.0674	0.0507	0.1844
rs7429135	G	T	NA	NA	0.0199	0.0034	5.92E-09	-0.0017	0.0525	0.9736
rs750472	C	A	NA	NA	-0.0216	0.0025	4.22E-18	0.0399	0.0459	0.3848
rs7694379	A	G	NA	NA	-0.042	0.0025	4.75E-62	0.0032	0.0393	0.935
rs7697204	T	C	NA	NA	-0.0295	0.0028	4.24E-25	0.0339	0.0435	0.4351
rs7922067	A	G	NA	NA	-0.0211	0.0025	1.18E-16	0.0321	0.041	0.4332
rs7947951	G	A	NA	NA	-0.0283	0.0027	9.37E-26	0.0112	0.0422	0.7914
rs7994151	G	A	NA	NA	-0.0206	0.0035	2.89E-09	-0.0014	0.0541	0.9799
rs8017377	A	G	NA	NA	-0.0342	0.0025	3.92E-42	0.0402	0.049	0.4126
rs8023580	C	T	NA	NA	0.073	0.0028	1.52E-150	-0.01	0.0459	0.8277
rs9316500	G	T	NA	NA	-0.0172	0.0027	3.05E-10	0.076	0.0413	0.06539
rs9388768	A	C	NA	NA	-0.0197	0.0027	1.39E-13	-0.0466	0.0434	0.2833
rs9427104	T	C	NA	NA	0.027	0.0025	4.04E-27	0.0235	0.0391	0.5472
rs9556403	G	A	NA	NA	0.0205	0.0026	4.66E-15	-0.0091	0.0399	0.8201
rs9644032	G	T	NA	NA	-0.0159	0.0026	1.03E-09	0.0315	0.041	0.4426
rs9892297	G	A	NA	NA	-0.1366	0.0026	1.00E-200	0.0168	0.0438	0.7011

SNP, single nucleotide polymorphism; FTD, frontotemporal dementia; GWAS, genome-wide association studies; NA, not available.




Figure S1 Scatter plots of serum SHBG level and neurodegenerative diseases (clump $R^2=0.00001$). Genome-wide significantly associated ($P<5\times 10^{-8}$) independent (linkage disequilibrium $R^2=0.00001$, clumping distance =10,000 kb) SNPs were used as instruments. SHBG, sex-hormone binding globulin; MR, Mendelian randomization; AD, Alzheimer's disease; PD, Parkinson's disease; ALS, amyotrophic lateral sclerosis; MS, multiple sclerosis; DLB, Dementia with Lewy Bodies; FTD, frontotemporal dementia.

Outcome	Method	No. of SNPs	OR & 95% CI	P value
Late-onset AD	Inverse variance weighted	193	0.971 (0.889-1.062)	0.525
	MR Egger	193	0.889 (0.758-1.043)	0.151
	Weighted median	193	0.871 (0.762-0.995)	0.042
	Weighted mode	193	0.883 (0.768-1.016)	0.083
Maternal AD	Inverse variance weighted	193	1.029 (0.929-1.140)	0.587
	MR Egger	193	0.960 (0.798-1.155)	0.666
	Weighted median	193	1.006 (0.846-1.197)	0.944
Paternal AD	Inverse variance weighted	193	0.992 (0.835-1.180)	0.931
	MR Egger	193	1.006 (0.889-1.139)	0.923
	Weighted median	193	0.978 (0.784-1.218)	0.840
PD	Inverse variance weighted	193	1.054 (0.832-1.335)	0.665
	MR Egger	193	0.988 (0.873-1.118)	0.848
	Weighted median	193	0.795 (0.638-0.990)	0.042
ALS	Inverse variance weighted	194	0.861 (0.733-1.013)	0.071
	MR Egger	194	0.827 (0.700-0.977)	0.027
	Weighted median	194	1.071 (0.985-1.165)	0.109
	Weighted mode	194	1.181 (1.016-1.373)	0.032
MS	Inverse variance weighted	186	1.169 (1.039-1.315)	0.009
	MR Egger	186	1.144 (0.916-1.429)	0.236
	Weighted median	186	1.065 (0.699-1.624)	0.769
	Weighted mode	186	0.871 (0.739-1.027)	0.099
DLB	Inverse variance weighted	181	0.865 (0.728-1.026)	0.098
	MR Egger	181	0.861 (0.706-1.050)	0.140
	Weighted median	181	1.380 (0.979-1.946)	0.067
	Weighted mode	181	1.093 (0.788-1.514)	0.595
FTD	Inverse variance weighted	157	1.197 (0.828-1.731)	0.340
	MR Egger	157	0.879 (0.688-1.124)	0.304
	Weighted median	157	0.789 (0.488-1.276)	0.335
	Weighted mode	157	0.884 (0.564-1.387)	0.592
			0.921 (0.590-1.436)	0.716

Figure S2 Mendelian randomization results of serum SHBG level and neurodegenerative diseases (clump $R^2=0.001$). Genome-wide significantly associated ($P<5\times 10^{-8}$) independent (linkage disequilibrium $R^2=0.001$, clumping distance =10,000 kb) SNPs were used as instruments. SHBG, Sex-hormone binding globulin; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; MR, Mendelian randomization; AD, Alzheimer's disease; PD, Parkinson's disease; ALS, amyotrophic lateral sclerosis; MS, multiple sclerosis; DLB, Dementia with Lewy Bodies; FTD, frontotemporal dementia.




Figure S3 Scatter plots of SHBG and neurodegenerative diseases (clump $R^2=0.001$). Genome-wide significantly associated ($P<5\times 10^{-8}$) independent (linkage disequilibrium $R^2=0.001$, clumping distance =10,000 kb) SNPs were used as instruments. SHBG, sex-hormone binding globulin; MR, Mendelian randomization; AD, Alzheimer's disease; PD, Parkinson's disease; ALS, amyotrophic lateral sclerosis; MS, multiple sclerosis; DLB, Dementia with Lewy Bodies; FTD, frontotemporal dementia.





Figure S4 Leave-one-out and single-SNP analyses of late-onset AD.





Figure S5 Leave-one-out and single-SNP analyses of maternal AD.





Figure S6 Leave-one-out and single-SNP analyses of paternal AD.





Figure S7 Leave-one-out and single-SNP analyses of PD.




Figure S8 Leave-one-out and single-SNP analyses of ALS.




Figure S9 Leave-one-out and single-SNP analyses of MS.





Figure 10 Leave-one-out and single-SNP analyses of DLB.





Figure S11 Leave-one-out and single-SNP analyses of FTD.